| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 121 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | EP06758843.4 | 2006-04-28 | EP1874117B1 | 2013-08-28 | JOHNS, Brian, Alvin; KAWASUJI, Takashi; TAISHI, Teruhiko; TAODA, Yoshiyuki |
| The present invention is to provide a novel compound shown below, having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. | ||||||
| 122 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE | EP06822311 | 2006-10-26 | EP1950212A4 | 2010-08-04 | YOSHIDA HIROSHI; KAWASUJI TAKASHI; TAISHI TERUHIKO; TAODA YOSHIYUKI |
| 123 | BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITING ACTIVITY | EP06714066 | 2006-02-20 | EP1852434A4 | 2010-01-13 | YOSHIDA HIROSHI; KAWASUJI TAKASHI; TAODA YOSHIYUKI |
| 124 | SPECIFIC KINASE INHIBITORS | EP05799606 | 2005-09-26 | EP1794137A4 | 2009-12-02 | SANTI DANIEL V; REID RALPH C; HUTCHINSON RICHARD C; SUNDERMANN KURT F; LAU JANICE |
| 125 | HETEROCYCLICAL CHROMOPHORE ARCHITECTURES WITH NOVEL ELECTRONIC ACCEPTOR SYSTEMS | EP06748934 | 2006-03-30 | EP1863774A4 | 2009-07-15 | GOETZ FREDERICK J |
| NLO chromophores for the production of first-, second, third- and/or higher order polarizabilities of the form of Formula I: R ( P ) Acc1 .Q4- Acc3 S/ ^Q1' n Acc4 Y A Formula I and the commercially acceptable salts, solvates and hydrates thereof, wherein n, p, X , Acc Z1*4, Q1'5, π\ D and A have the definitions provided herein. | ||||||
| 126 | HETEROCYCLICAL CHROMOPHORE ARCHITECTURES WITH NOVEL ELECTRONIC ACCEPTOR SYSTEMS | EP06748934.4 | 2006-03-30 | EP1863774A2 | 2007-12-12 | GOETZ, Frederick J. |
| NLO chromophores for the production of first-, second, third- and/or higher order polarizabilities of the form of Formula I: R ( P ) Acc1 .Q4- Acc3 S/ ^Q1' n Acc4 Y A Formula I and the commercially acceptable salts, solvates and hydrates thereof, wherein n, p, X , Acc Z1*4, Q1'5, π\ D and A have the definitions provided herein. | ||||||
| 127 | HETEROARYL SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | EP06718423.4 | 2006-01-13 | EP1836203A2 | 2007-09-26 | CALDWELL, Timothy M.; CHENARD, Bertrand; HODGETTS, Kevin |
| Heteroaryl substituted quinolin-4-ylamine analogues of Formula (I) are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. | ||||||
| 128 | SPECIFIC KINASE INHIBITORS | EP05799606.8 | 2005-09-26 | EP1794137A2 | 2007-06-13 | SANTI, Daniel, V.; REID, Ralph, C.; HUTCHINSON, Richard, C.; SUNDERMANN, Kurt, F.; LAU, Janice |
| Resorcylic acid lactones having a C5-C6 cis double bond and a ketone at C7 and other compounds capable of Michael adduct formation are potent and stable inhibitors of a subset of protein kinases having a specific cysteine residue in the ATP binding site. | ||||||
| 129 | SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS | EP04751255 | 2004-05-03 | EP1619948A4 | 2007-02-14 | XU YUELIAN; HAN BINGSONG; XIE LINGHONG |
| 130 | Spojine, ki vsebujejo nitril, ki se uporabljajo kot protivirusna sredstva za zdravljenje okužbe s koronavirusom | SI202130014 | 2021-08-06 | SI3953330T1 | 2023-01-31 | OWEN DAFYDD RHYS; PETTERSSON MARTIN YOUNGJIN; REESE MATTHEW RICHARD; SAMMONS MATTHEW FORREST; TUTTLE JAMISON BRYCE; VERHOEST PATRICK ROBERT; WEI LIUQING; YANG QINGYI; YANG XIAOJING |
| 131 | 2-okso-tiazolni derivati kot zaviralci A2A in spojine za uporabo pri zdravljenju raka | SI201830747 | 2018-03-30 | SI3601296T1 | 2022-10-28 | CROSIGNANI STEFANO; GOMES BRUNO; HOUTHUYS ERICA |
| 132 | Sulfonic acid ester compound and preparation method and application thereof | LU500253 | 2021-06-07 | LU500253B1 | 2021-12-07 | SHEN RUNPU; CAI TAO; LIU JIAN; WU CHUNLEI; XI MEIYANG; GAO XIAOZHONG; FENG CHENGJIE; DU KUI |
| The application discloses a sulfinate compound, a preparation method and application thereof, and the structural formula of the sulfinate compound is shown as formula 1. In this application, 5- alkyl -3-[ 5- alkyl -2- hydroxyphenyl] benzofuran -2-( 3-hydro)-ketone is used as raw material, and reacts with thionyl chloride in the presence of inert organic solvent to prepare sulfinate compounds. The sulfinate compounds prepared above have obvious inhibitory effects on gastric cancer cells, melanoma cells, lung cancer cells, etc., and can be used to prepare novel compounds. | ||||||
| 133 | Antibakterijske spojine, ki imajo širok spekter aktivnosti | SI201531377 | 2015-12-14 | SI3233827T1 | 2020-11-30 | OMBRATO ROSELLA; GAROFALO BARBARA; MANGANO GIORGINA; CAPEZZONE DE JOANNON ALESSANDRA; CORSO GAIA; CAVARISCHIA CLAUDIA; FURLOTTI GUIDO; IACOANGELI TOMMASO |
| 134 | composto, composição farmacêutica, e, uso de um composto | BRPI0610030 | 2006-04-28 | BRPI0610030B1 | 2020-09-15 | BRIAN ALVIN JOHNS; TAKASHI KAWASUJI; YOSHIYUKI TAODA; TERUHIKO TAISHI |
| composto, processo para a preparação de um composto, método de tratamento de uma infecção por hiv em um humano, uso de um composto, e, composição farmacêutica. a presente invenção é para fornecer um novo composto (i), tendo a atividade anti-vírus, particularmente a atividade inibitória da integrase hiv, e um medicamento contendo a mesma, particularmente, um medicamento anti-hiv, bem como um processo e um seu intermediário. o composto (i), (l) em que z1 é nr4; r1 é hidrogênio ou alquila inferior; x é uma ligação simples, um grupo hetero átomo selecionado de o, s, so, so2 e nh, ou alquileno inferior ou alquenileno inferior, em que o grupo hetero átomo pode intervir; r2 é arila opcionalmente substituída; r3 é hidrogênio, um halogêneo, hidróxi, alquila inferior opcionalmente substituída etc; e r4 e a parte z2 tomados juntos formam um anel, para formar um composto policíclico, incluindo, p. ex., um composto tricíclico ou tetracíclico. | ||||||
| 135 | ACC INHIBITORJI IN NJIHOVA UPORABA | SI201231264 | 2012-11-09 | SI2776038T1 | 2018-06-29 | HARRIMAN GERALDINE C; MASSE CRAIG E; HARWOOD JAMES; BHAT SATHESH; GREENWOOD JEREMY ROBERT |
| 136 | СПОСІБ СЕЛЕКТИВНОГО ОКИСНЕННЯ СУЛЬФІДУ ДО СУЛЬФОКСИДУ | UAA201502841 | 2015-03-27 | UA112712C2 | 2016-10-10 | |
| Данийвинахідстосуєтьсягалузіорганічноїхімії, зокремахіміїгетероциклічнихсполук, асамеспособуселективногоокисненнясульфідудосульфоксидунаприкладі 1,5-бензоксатієпінуз метоюодержаннярозширеногоасортиментусполук, якіможутьбутизастосованів медициніяксполукидляодержанняфізіологічноактивнихречовин.Технічнийрезультат: доступністьреагентів; високийвихідцільовихпродуктів - 72 % та 75 %, відповідно; відсутністьпотребиу використаннідодатковихокисникатакаталізатора; простотавиділенняпродуктівреакцій; виділеннячистихсполук, якінепотребуютьдодатковоїочистки. | ||||||
| 137 | HETEROCYCLICAL CHROMOPHORE ARCHITECTURES | CA2584792 | 2005-10-26 | CA2584792C | 2016-05-24 | GOETZ FREDERICK J; GOETZ FREDERICK J JR |
| (see formula I) NLO chromophores of the form of Formula I and the commercially acceptable salts, solvates and hydrates thereof, wherein Z1-4, X1-4, ,.pi.1-4, D and A have the definitions provided herein. The heterocyclical nature of these systems prevents the existence of photo-induced cis-trans isomerization, which is suspected as a cause of both material and molecular degeneration. | ||||||
| 138 | ΠΟΛΥΚΥΚΛΙΚΟ ΠΑΡΑΓΩΓΟ ΚΑΡΒΑΜΟΫΛΠΥΡΙΔΟΝΗΣ ΠΟΥ ΕΧΕΙ ΑΝΑΣΤΑΛΤΙΚΗ ΔΡΑΣΤΗΡΙΟΤΗΤΑ ΙΝΤΕΓ(Κ)ΡΑΣΗΣ [ΕΝΣΩΜΑΤΑΣΗΣ] ΤΟΥ HIV | CY131101061 | 2013-11-27 | CY1115151T1 | 2015-12-09 | JOHNS BRIAN ALVIN; KAWASUJI TAKASHI; TAISHI TERUHIKO; TAODA YOSHIYUKI |
| Ηπαρούσαεφεύρεσηπρόκειταιναπαράσχεικαινοφανήένωση (Ι), πουέχειτηνδραστηριότητακατάτουιού, ειδικότεραδετηνανασταλτικήδραστηριότητατηςιντεγκράσηςτουΗIV, καιφάρμακοπουπεριέχειτηνίδια, ειδικότεραφάρμακοκατάτουΗIV, ωςεπίσηςκαιδιεργασίακαιενδιάμεσοπροϊόνεξαυτής. Ηένωση (Ι) όπουτοΖ1 είναιΝR4· το R1 είναιυδρογόνοή κατώτεροαλκύλιο· τοΧ είναιμονόςδεσμός, ομάδαετεροατόμουπουεπιλέγεταιαπόΟ, S, SO, SO2 καιΝΗ, ήκατώτεροαλκυλένιοή κατώτεροαλκενυλένιοσταοποίαη ομάδαετεροατόμουμπορείναπαρέμβει· το R2 είναιπροαιρετικώςυποκατεστημένοαρύλιο·το R3 είναιυδρογόνο, αλογόνο, υδροξυομάδα, προαιρετικώςυποκατεστημένοκατώτεροαλκύλιοκλπ·καιτομέροςτων R4 καιΖ2 ληφθέναπόκοινούσχηματίζειδακτύλιο, γιανασχηματιστείπολυκυκλικήένωση, πουσυμπεριλαμβάνειπχ., τρικυκλικήή τετρακυκλικήένωση. | ||||||
| 139 | ПОХІДНІ Й АНАЛОГИ N-ЕТИЛХІНОЛОНІВ І N-ЕТИЛАЗАХІНОЛОНІВ | UAA200900417 | 2007-07-18 | UA99440C2 | 2012-08-27 | BALLELL LLUIS; BARROS DAVID; BROOKS GERALD; CASTRO PICHEL JULIA; DABBS STEVEN; DAINES ROBERT A; DAVIES DAVID THOMAS; FIANDOR ROMAN JOSE MARIA; GIORDANO ILARIA; HENNESSY ALAN JOSEPH; HOFFMAN JAMES B; JONES GRAHAM ELGIN; MILES TIMOTHY JAMES; PEARSON NEIL DAVID; PENDRAK ISRAIL; REMUINAN BLANCO MODESTO J; ROSSI JASON ANTHONY; ZHANG LIHUA LILY |
| Винахідстосуєтьсябіциклічнихазотовміснихсполуктаїхзастосуванняякпротибактерійнихзасобів. | ||||||
| 140 | ГЕПТАЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ДИАБЕТА И МЕТАБОЛИЧЕСКОГО СИНДРОМА | UAA200913731 | 2007-05-29 | UA96339C2 | 2011-10-25 | SHEN JIANHUA; LENG YING; JIANG HUALIANG; CHEN JUNHUA |
| Изобретениеописываетприменениеновогоклассагептациклическихсоединенийдляполучениярецептурдляпрофилактикии лечениидиабетаи метаболическогосиндрома; представленноеизобретениетакжеописываетновыйклассгептациклическихсоединений; представленноеизобретениетакжеописываетспособполучениягептациклическихсоединенийи композицию, котораяихсодержит.Гептациклическиесоединенияпредставленногоизобретениямогутбытьиспользованыдляэффективнойпрофилактикиилилечениязаболеваний, такихкакдиабети метаболическийсиндром.(I) | ||||||
QQ群二维码
意见反馈
意见反馈